ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AUPH Aurinia Pharmaceuticals Inc

5.03
0.00 (0.00%)
Pre Market
Last Updated: 07:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1
Bid Price 4.87
Ask Price 5.01
News -
Day High

Low
4.71

52 Week Range

High
12.43

Day Low
Company Name Stock Ticker Symbol Market Type
Aurinia Pharmaceuticals Inc AUPH NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 5.03 07:00:00
Open Price Low Price High Price Close Price Prev Close
5.03
Trades Volume Avg Volume 52 Week Range
1 1 - 4.71 - 12.43
Last Trade Time Type Quantity Stock Price Currency
07:00:00 1 $ 5.01 USD

Aurinia Pharmaceuticals (AUPH) Options Flow Summary

Overall Flow

Bearish

Net Premium

-66k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

Aurinia Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
727.43M 144.62M - 175.51M -78.02M -0.54 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Aurinia Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No AUPH Message Board. Create One! See More Posts on AUPH Message Board See More Message Board Posts

Historical AUPH Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.925.164.714.961,309,0900.112.24%
1 Month4.995.414.715.061,309,9450.040.80%
3 Months7.628.504.715.882,145,447-2.59-33.99%
6 Months7.4710.054.717.252,087,563-2.44-32.66%
1 Year10.6612.434.718.622,165,608-5.63-52.81%
3 Years12.6533.97154.0712.492,939,408-7.62-60.24%
5 Years6.2633.97153.5213.012,510,403-1.23-19.65%

Aurinia Pharmaceuticals Description

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.

Your Recent History

Delayed Upgrade Clock